# RevSTAR-123 (NCT05949125)

> Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05949125
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: AvenCell Europe GmbH
- Conditions: Acute Myeloid Leukemia, in Relapse; Acute Myeloid Leukemia Refractory
- Interventions: Cyclophosphamide (Non-IMP, Lymphodepletion); Fludarabine (Non-IMP, Lymphodepletion); R-TM123; Allo-RevCAR01-T
- Enrollment: 37
- Primary outcome: Safety and tolerability

## Indexed commentary on RevSTAR-123 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=revstar-123-nct05949125